WuXi STA opens large-scale oligonucleotide manufacturing facility

6 Jan 2020

Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.

STA Pharmaceutical (WuXi STA) – a subsidiary of WuXi AppTec – has opened its large-scale oligonucleotide API manufacturing facility in Changzhou, China. This significant milestone marks WuXi STA’s establishment of a comprehensive one-stop platform to support the process R&D and manufacture of oligonucleotide APIs from preclinical to commercial. It enables customers around the world to advance promising new oligonucleotide therapies more rapidly to market.

WuXi STA opens large-scale oligonucleotide manufacturing facility

Nucleic acid drugs have gradually become a hot area in the global innovative drug industry and many nucleic acid drugs have been approved by the FDA in recent years. The new facility, with over 30,000 sq. ft, is located at WuXi STA’s Changzhou site. With its operation, the Changzhou site can manufacture oligonucleotide APIs up to 1 mol/synthesis run, to better meet the increasing demand of its customers.

WuXi STA’s comprehensive platform covers the development and manufacturing of a variety of oligonucleotide modalities including DNA, RNA, Morpholino oligonucleotide (PMO) and peptide conjugates (PPMO). In addition, the company’s small molecule process chemistry organization adds further value in handling complex conjugation chemistry that involves oligonucleotide and other molecular modalities, as well as a combination of solid and solution phase chemistry to support next-generation oligonucleotide manufacturing technology development.

“By leveraging our small-molecule CMC (chemical, manufacturing, and control) technology and capability platform as well as global standard quality system, WuXi STA provides a robust one-stop shop for oligonucleotide innovators. The opening of this large-scale manufacturing facility will empower more global partners to expedite the development and commercialization of oligonucleotide drugs to benefit patients worldwide,” commented Dr Minzhang Chen, CEO of WuXi STA.

Read More

Related categories

Related tags

Market News

Related news

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

US drug regulator, the Food and Drug Administration has ordered the immediate withdrawal of all prescription and over-the-counter versions of heartburn drug, ranitidine – commonly known as Zantac – after concluding certain products may present an incre...

Read more 
UPDATED: COVID-19 PHARMA TRACKER

UPDATED: COVID-19 PHARMA TRACKER

2 Apr 2020

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

China is stepping up its efforts to produce and ship active pharmaceutical ingredients (APIs), with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease, according to Chinese officials Tuesday.

Read more 
New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
Cambrex names Troy Player as head of early stage development and testing

Cambrex names Troy Player as head of early stage development and testing

31 Mar 2020

Cambrex has appointed pharma industry veteran, Troy Player, as president, early stage development and testing, the contract development and manufacturing organisation said Tuesday.

Read more 
CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

CDMO Ritedose chooses ChargePoint to ensure drug substance mixing process sterility

31 Mar 2020

The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered with ChargePoint Technology to ensure the sterility of its drug substance mixing process.

Read more 
EMA to only issue electronic medicines certificates during COVID-19 pandemic

EMA to only issue electronic medicines certificates during COVID-19 pandemic

30 Mar 2020

The European Medicines Agency (EMA) said Monday it will only issue electronically signed and authenticated certificates for human and veterinary medicines in place of printed ones so it can continue to provide the documents during the COVID-19 pandemic...

Read more 
PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

PandemiCam — our greatest chance yet to detect, monitor and beat COVID-19?

30 Mar 2020

Joint venture between Spinview and VR Media Technology creates device that provides accurate and fast detection of infectious people with far greater clarity than any single parameter test available today.

Read more 
New device offers a convenient way to monitor compressed air for viable particles

New device offers a convenient way to monitor compressed air for viable particles

30 Mar 2020

Specialist cleanroom microbiology solutions company offers the new SAS Super Pinocchio CR compressed air sampling device.

Read more 
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

25 Mar 2020

Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

Read more